miR-17-3p contributes to exercise-induced cardiac growth and protects against myocardial ischemia-reperfusion injury
Shi, Jing; Bei, Yihua; Kong, Xiangqing; Liu, Xiaojun; Lei, Zhiyong; Xu, Tianzhao; Wang, Hui; Xuan, Qinkao; Chen, Ping; Xu, Jiahong; Che, Lin; Liu, Hui; Zhong, Jiuchang; Sluijter, Joost P.G.; Li, Xinli; Rosenzweig, Anthony; Xiao, Junjie
(2017) Theranostics, volume 7, issue 3, pp. 664 - 676
(Article)
Abstract
Limited microRNAs (miRNAs, miRs) have been reported to be necessary for exercise-induced cardiac growth and essential for protection against pathological cardiac remodeling. Here we determined members of the miR-17-92 cluster and their passenger miRNAs expressions in two distinct murine exercise models and found that miR-17-3p was increased in both. miR-17-3p
... read more
promoted cardiomyocyte hypertrophy, proliferation, and survival. TIMP-3 was identified as a direct target gene of miR-17-3p whereas PTEN was indirectly inhibited by miR-17-3p. Inhibition of miR-17-3p in vivo attenuated exercise-induced cardiac growth including cardiomyocyte hypertrophy and expression of markers of myocyte proliferation. Importantly, mice injected with miR-17-3p agomir were protected from adverse remodeling after cardiac ischemia/reperfusion injury. Collectively, these data suggest that miR-17-3p contributes to exercise-induced cardiac growth and protects against adverse ventricular remodeling. miR-17-3p may represent a novel therapeutic target to promote functional recovery after cardiac ischemia/reperfusion.
show less
Download/Full Text
Keywords: Cardiac growth, Exercise, microRNA, Medicine (miscellaneous), Pharmacology, Toxicology and Pharmaceutics (miscellaneous), Journal Article
Publisher: Ivyspring International Publisher
Note: Funding Information: This work was supported by the grants from National Natural Science Foundation of China (81570362, 91639101, and 81200169 to JJ Xiao, 81370332 and 81170201 to XL Li, 81400647 to Y Bei, 81370362 to JC Zhong), NIH (R21HL114352, 1UH2TR000901, R01HL110733 to A Rosenzweig), the Priority Academic Program Development of Jiangsu Higher Education Institutions (PAPD20102013 to XL Li), the Netherlands Cardiovascular Research Initiative (CVON): the Dutch Heart Foundation, Dutch Federation of University Medical Centers, the Netherlands Organization for Health Research and Development, and the Royal Netherlands Academy of Science (to JPG Sluijter), the National Basic Research Program of China (2014CB542300), the National Major Research Plan Training Program (91339108), Shanghai Municipal Education Commission-Gaofeng Clinical Medicine Grant (20152509). Dr XQ Kong is a Fellow and Dr XL Li is an Associate Fellow at the Collaborative Innovation Center For Cardiovascular Disease Translational Medicine. Publisher Copyright: © Ivyspring International Publisher.
(Peer reviewed)